IL1B and infection: For instance, in the recent CANTOS5 clinical trial that evaluated the anti-inflammatory effects of the interleukin-1 beta (IL-1β) neutralizing monoclonal antibody canakinumab in cardiovascular disease, a reduction in cardiovascular events was observed at the cost of a significantly increased risk of death from infection and sepsis.